[HTML] mdpi.com

[HTML][HTML] Novel biomarkers and druggable targets in advanced melanoma

PF Ferrucci, E Cocorocchio - Cancers, 2021 - mdpi.com
Simple Summary Immunotherapy and targeted therapy represent effective therapeutic
opportunities that radically changed the available armamentarium for the treatment of …
被引用次数：7 相关文章

Novel Biomarkers and Druggable Targets in Advanced Melanoma.

PF Ferrucci, E Cocorocchio - Cancers, 2022 - search.ebscohost.com
Abstract Simple Summary: Immunotherapy and targeted therapy represent effective
therapeutic opportunities that radically changed the available armamentarium for the …

Novel Biomarkers and Druggable Targets in Advanced Melanoma

PF Ferrucci, E Cocorocchio - Cancers, 2021 - pubmed.ncbi.nlm.nih.gov
Immunotherapy with Ipilimumab or antibodies against programmed death (ligand) 1 (anti-
PD1/PDL1), targeted therapies with BRAF-inhibitors (anti-BRAF) and their combinations …

Novel Biomarkers and Druggable Targets in Advanced Melanoma.

PF Ferrucci, E Cocorocchio - Cancers, 2021 - europepmc.org
Immunotherapy with Ipilimumab or antibodies against programmed death (ligand) 1 (anti-
PD1/PDL1), targeted therapies with BRAF-inhibitors (anti-BRAF) and their combinations …

Novel Biomarkers and Druggable Targets in Advanced Melanoma

PF Ferrucci, E Cocorocchio - Cancers, 2022 - search.proquest.com
Immunotherapy with Ipilimumab or antibodies against programmed death (ligand) 1 (anti-
PD1/PDL1), targeted therapies with BRAF-inhibitors (anti-BRAF) and their combinations …
[HTML] nih.gov

[HTML][HTML] Novel Biomarkers and Druggable Targets in Advanced Melanoma

PF Ferrucci, E Cocorocchio - Cancers, 2022 - ncbi.nlm.nih.gov
Immunotherapy with Ipilimumab or antibodies against programmed death (ligand) 1 (anti-
PD1/PDL1), targeted therapies with BRAF-inhibitors (anti-BRAF) and their combinations …